A Phase 2 interventional study of ADX-629 (Open-label) in Atopic Dermatitis, sponsored by Aldeyra Therapeutics, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Aldeyra Therapeutics, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 639 studies in Dermatitis, Atopic with a site in United States — 78 open to participants now, 117 under way, 18 of them phase 3. Dermatitis, Atopic · United States.
Among the 639 studies in Dermatitis, Atopic with a site in United States, this one is the 508th largest by enrollment of the 544 interventional ones that give a count, is one of 50 that started in 2023, is one of 202 in phase 2, and was the 496th registered.
1,596 studies on the registry are indexed under Dermatitis, Atopic; 289 are open to participants now.
Browse Dermatitis, Atopic studies →78 of the 639 studies in Dermatitis, Atopic with a site in United States are open now. Recruiting first, the newest first:
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 12–120
Weill Medical College of Cornell University · Sites in United States
Ages 13–17
Arcutis Biotherapeutics, Inc. · Sites in United States
Ages 6+
Triveni Bio · Sites in United States, Canada, Ukraine
Ages 18–75
Pfizer · Sites in United States, Canada, Japan and 1 more country
Ages 12+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 195 Dermatitis, Atopic studies recruiting now, 84 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
639 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 97 · Phase 2 221 · Phase 3 107 · Phase 4 70
First in 1996; this study’s year is marked. 50 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 8 is below the median of 82 across 1,249 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 96 across the 544 interventional studies, 155 across the 94 observational. Of the 491 that completed or were terminated, 265 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
429 of 639 have an industry lead sponsor. The 10 most frequent:
Aldeyra Therapeutics, Inc. is the lead sponsor of 35 studies on the registry; 1 is open to participants now.
Of its 29 completed or terminated interventional studies of FDA-regulated products, 25 (86%) have results posted.
Aldeyra Therapeutics, Inc. has 1 study filed under Dermatitis, Atopic — fewer than ten, so there is no comparison to draw.
42 of the studies in Dermatitis, Atopic with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06389136Phase 3AbbVieA Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab | 2026-11 |
| NCT07355075Phase 3Turn TherapeuticsA Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema) | 2027-01-20 |
| NCT07265479Phase 3Organon and CoA Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis | 2027-08 |
| NCT06241118Phase 3SanofiA Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor | 2027-09-30 |
| NCT06395948Apogee Therapeutics, Inc.A Study Evaluating APG777 in Atopic Dermatitis | 2026-11 |
Add all 42 to your calendar (.ics) → With an account.
Among the 639 studies in Dermatitis, Atopic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A Phase 2, multicenter, adaptive 2-part clinical trial designed to evaluate the safety and efficacy of ADX-629 alone and in combination with standard-of-care in adults with atopic dermatitis.
The trial is divided into 2 parts; the first part of the trial (Part 1) is open label, and the second part (Part 2) is randomized, double-blind, and placebo controlled.
In Part 1, approximately 10 subjects will receive open-label ADX-629 twice daily for 90 days.
In Part 2, approximately 40 subjects will be randomized to receive either ADX-629 or matching placebo twice daily for 90 days.
Patients who are interested in participating will be provided detailed information about the study including description of study assessments/procedures, possible side-effects, alternative treatments, and potential benefits.
The criteria were revised on the registry on Nov 10, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: ADX-629 (Open-label)
ADX-629 (250 mg) administered twice daily for 90 days
Number of Subjects With Serious Adverse Events
The proportion of subjects that experience at least one serious adverse event
Time frame: The safety assessment period was approximately 15 weeks.
Proportion of Subjects Achieving ≥ 4 Point Improvement in the Peak Pruritus Numerical Rating Scale
The Peak Pruritus Numerical Rating Scale is an eleven-point scale (0 = no itch, 10 = worst itch imaginable).
Time frame: The efficacy assessment period was from Day 1 to Day 90.
Proportion of Subjects With a ≥ 50% Improvement in Eczema Area and Severity Index (EASI) Score at Day 90
The total EASI score ranges from 0 to 72, with a higher score indicating more severe disease.
Time frame: The efficacy assessment period was Day 90.
| Milestone | ADX-629 | ADX-629 and Topical Therapy | ADX-629 and Dupilumab |
|---|---|---|---|
| Started | 5 | 2 | 1 |
| Completed | 5 | 2 | 1 |
| Not completed | 0 | 0 | 0 |
The proportion of subjects that experience at least one serious adverse event
| Participants | ADX-629 | ADX-629 and Topical Therapy | ADX-629 and Dupilumab |
|---|---|---|---|
| Number of Subjects With Serious Adverse Events | 0 | 0 | 0 |
The Peak Pruritus Numerical Rating Scale is an eleven-point scale (0 = no itch, 10 = worst itch imaginable).
| Participants | ADX-629 | ADX-629 and Topical Therapy | ADX-629 and Dupilumab |
|---|---|---|---|
| Proportion of Subjects Achieving ≥ 4 Point Improvement in the Peak Pruritus Numerical Rating Scale | 5 | 2 | 1 |
The total EASI score ranges from 0 to 72, with a higher score indicating more severe disease.
| Participants | ADX-629 | ADX-629 and Topical Therapy | ADX-629 and Dupilumab |
|---|---|---|---|
| Proportion of Subjects With a ≥ 50% Improvement in Eczema Area and Severity Index (EASI) Score at Day 90 | 4 | 0 | 0 |
Collected over The safety assessment period was approximately 15 weeks.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ADX-629 | 0/5 (0%) | 0/5 (0%) | 4/5 (80%) |
| ADX-629 and Topical Therapy | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) |
| ADX-629 and Dupilumab | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Event | ADX-629 | ADX-629 and Topical Therapy | ADX-629 and Dupilumab |
|---|---|---|---|
| Groin painMusculoskeletal and connective tissue disorders | 0/5 | 0/2 | 1/1 |
| Musculoskeletal chest painMusculoskeletal and connective tissue disorders | 0/5 | 0/2 | 1/1 |
| MyalgiaMusculoskeletal and connective tissue disorders | 0/5 | 0/2 | 1/1 |
| Upper respiratory infectionInfections and infestations | 2/5 | 0/2 | 0/1 |
| Urinary tract infectionInfections and infestations | 1/5 | 0/2 | 0/1 |
| FlatulenceGeneral disorders | 1/5 | 0/2 | 0/1 |
| Tooth fractureInjury, poisoning and procedural complications | 1/5 | 0/2 | 0/1 |
| AnxietyPsychiatric disorders | 1/5 | 0/2 | 0/1 |
| InsomniaPsychiatric disorders | 1/5 | 0/2 | 0/1 |
| Menstrual disorderReproductive system and breast disorders | 1/5 | 0/2 | 0/1 |
Safety population
| Age, Continuous(years) | ADX-629 | ADX-629 and Topical Therapy | ADX-629 and Dupilumab | Total |
|---|---|---|---|---|
| Mean | 40.2 ± 18.02 | 44.0 ± 8.49 | 30.0 ± NA | 39.9 ± 14.65 |
| Sex: Female, Male(Participants) | ADX-629 | ADX-629 and Topical Therapy | ADX-629 and Dupilumab | Total |
|---|---|---|---|---|
| Female | 4 | 1 | 0 | 5 |
| Male | 1 | 1 | 1 | 3 |
| Ethnicity (NIH/OMB)(Participants) | ADX-629 | ADX-629 and Topical Therapy | ADX-629 and Dupilumab | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 5 | 2 | 1 | 8 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | ADX-629 | ADX-629 and Topical Therapy | ADX-629 and Dupilumab | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 0 | 1 |
| White | 5 | 1 | 1 | 7 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2023 to primary completion in Nov 2023, 9 months.
Results were first posted in Nov 2026, 2 years 11 months after primary completion. A results delay was requested in Oct 2024.
Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 9 months is below that.
Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ADX-629